DexCom, Inc. research snapshot
DXCM AI stock analysis currently reads DexCom, Inc. as a high-quality continuous glucose monitoring business with recurring sensor demand, strong cash generation, record new patient starts, and an improving margin trend. The setup is not a certain price prediction. At the August 2, 2026 cutoff, the reference close was $83.45 on July 31, 2026, market capitalization was about $31.49 billion, and the main debate was whether G7 15 Day, Stelo, international growth, and margin expansion can keep offsetting Abbott competition, reimbursement pressure, and a premium valuation. This page is informational research and not investment advice.
Current price
$83.45
Market cap
$31.49 billion
AI score
78 / 100
Rating
High-quality CGM compounder with improved momentum and valuation checks
Trend status
Post-earnings uptrend above key moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Dexcom sells CGM systems for diabetes and metabolic health, with recurring sensor replacement creating subscription-like demand as the installed base grows. | High |
| Moat | The moat comes from clinical trust, sensor accuracy, payer access, app and cloud workflow integration, manufacturing scale, and patient switching friction. | Medium-high |
| Management | CEO Jake Leach led a Q2 2026 beat with record new patient starts, a raised 2026 outlook, a new long-term plan through 2030, and continued buybacks while Kevin Sayer serves as Executive Chairman. | Medium |
| Financial trend | Q2 2026 revenue rose 13% to $1.308 billion, GAAP net income reached $249.1 million, and GAAP operating margin expanded 590 basis points year over year to 24.3%. | High |
| Valuation | At about 32.9 times trailing EPS, 6.3 times sales, and 22.4 times free cash flow, DXCM still prices in durable double-digit growth and continued margin expansion. | Medium |
| Technical trend | The stock jumped to $83.45 after earnings and closed above its 50-day and 200-day moving averages, with RSI near 69 but still below the 52-week high of $87.00. | Medium |
| Risk level | Risk is moderate because device accuracy, reimbursement, channel mix, Abbott competition, GLP-1 substitution, and valuation can offset strong CGM adoption. | Medium-high |
| AI confidence | High for reported financials and business model mapping, medium for industry share estimates, and lower for future multiple assumptions. | High data confidence |
| Investment certainty | Medium certainty for business quality, but no automatic buy signal because valuation discipline, competition, and risk controls matter. | Medium |
DXCM AI stock forecast
The DXCM AI stock forecast uses scenario ranges from the $83.45 reference quote and a three-year earnings framework. These are conditional ranges, not guaranteed targets, and should be updated after earnings, product news, reimbursement changes, or a major technical break.
$120 to $135
More likely if revenue compounds in the mid-teens, G7 15 Day and Stelo expand the user base, non-GAAP operating margin reaches the guided 23.5% to 24% range, and the market rewards Dexcom with a premium medical-device multiple.
$95 to $105
More likely if 2026 guidance of $5.18 billion to $5.25 billion revenue is met, EPS moves toward the roughly $3.10 consensus for 2027, and investors value DXCM near a mid-20s earnings multiple.
$68 to $78
More likely if Abbott gains more share, GLP-1 substitution or pricing and rebate headwinds worsen, or growth investors compress the multiple toward a lower device peer range.
DXCM AI technical analysis
DXCM AI technical analysis uses the July 31, 2026 close and provider-published moving averages. The chart turned constructive after the July 30, 2026 earnings release, with price well above the 50-day and 200-day averages, but the stock is extended after a single-day gain of about 12% and sits just below its 52-week high.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $83.45 close on July 31, 2026 | StockAnalysis reported the July 31, 2026 close at $83.45 after Q2 results; use live quotes before trading. |
| Near support | $79.50 to $80.00 | This gap area marks the July 31 open and intraday low zone after the post-earnings jump. |
| Deeper support | $73.00 to $74.50 | This band overlaps the 50-day moving average and the pre-earnings close of $74.54; a close below it would weaken the breakout. |
| Near resistance | $84.70 to $87.00 | The stock faces the July 31 high of $84.70 and the 52-week high of $87.00. |
| 50-day moving average | $73.13 | StockAnalysis reported the 50-day moving average near $73.13 as of August 2, 2026. |
| 200-day moving average | $67.75 | The stock is well above the 200-day moving average, which supports a constructive trend reading. |
| Momentum | Positive but extended | StockAnalysis reported RSI near 68.6, suggesting strong momentum with limited room before an overbought reading. |
| Volume | About 12.0 million shares on July 31 | The earnings-day volume was well above the 20-day average of about 4.8 million, adding confirmation to the breakout. |
| Volatility | Elevated versus broad market | A 1.41 five-year beta and medical-device event risk make position sizing important. |
| Invalidation | Close below $73 | A decisive close below the 50-day moving average area would challenge the post-earnings breakout and reset the setup. |
DXCM AI trading strategy
The DXCM AI trading strategy is a rules-based research framework, not personalized advice. It pairs recurring-revenue business quality with chart confirmation, position sizing, and explicit invalidation levels.
Wait for DXCM to hold above the $79.50 to $80.00 breakout area and close above $87 with volume before treating the new uptrend as confirmed.
A close back below $73 or a negative product, reimbursement, or competitive update should invalidate the setup.
If DXCM pulls back to $73 to $79 without a fundamental thesis break, compare the pullback with revenue guidance, CGM share data, free cash flow, and margin evidence.
Do not average down unless maximum loss, event risk, and holding period are defined before entry.
Track G7 15 Day adoption, Stelo uptake, U.S. channel mix, international growth, Abbott Libre competition, Medtronic integration moves, gross margin, operating margin, and free cash flow.
Reduce confidence if revenue growth remains positive but patient starts, pricing, product trust, or cash conversion deteriorate.
Investment research summary
Customers pay Dexcom for real-time glucose data that supports diabetes decisions, caregiver monitoring, clinician workflow, and metabolic health tracking.
The moat is strongest where accuracy, brand trust, reimbursement, clinician familiarity, phone and cloud integrations, manufacturing scale, and patient habits reinforce each other. Mordor Intelligence estimated Dexcom held about 33.9% of 2025 CGM revenue versus Abbott at about 52.8%.
The thesis fails if Abbott or Medtronic reduce Dexcom differentiation, GLP-1 drugs lower testing frequency, reimbursement pressure lowers price, quality or product trust issues return, or the market refuses a premium multiple.
Management produced a Q2 2026 beat, record new patient starts, a raised 2026 outlook, and a new long-term plan through 2030, but CEO succession and capital allocation discipline still need ongoing monitoring.
CGM adoption remains a long-duration health-care trend. Mordor Intelligence forecast the CGM market growing from about $13.8 billion in 2025 to $31.8 billion in 2031, near a 15% CAGR, as diabetes, over-the-counter metabolic health, and remote monitoring use cases expand.
DXCM is not priced like a distressed device company. At about 33 times trailing earnings and 22 times free cash flow, margin of safety depends on durable growth, margin expansion, and avoiding a reset in medical-device multiples.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DXCM price | $83.45 close on July 31, 2026 | StockAnalysis DXCM overview | August 2, 2026 |
| Market cap and shares | $31.49 billion market cap, 377.36 million shares outstanding | StockAnalysis DXCM statistics | August 2, 2026 |
| Q2 2026 revenue | $1.308 billion, up 13% year over year, with U.S. up 11% and international up 19% | Dexcom Q2 2026 results | August 2, 2026 |
| Q2 2026 net income and EPS | $249.1 million GAAP net income, $0.64 diluted EPS, $0.70 non-GAAP diluted EPS | Dexcom Q2 2026 results | August 2, 2026 |
| Q2 2026 margins | GAAP operating income of $318.3 million or 24.3% of revenue, up 590 basis points year over year | Dexcom Q2 2026 results | August 2, 2026 |
| Cash and liquidity | $1.95 billion cash, cash equivalents and marketable securities, with the revolving credit facility undrawn | Dexcom Q2 2026 results | August 2, 2026 |
| 2026 revenue guidance | Raised to $5.18 billion to $5.25 billion, about 11% to 13% growth | Dexcom Q2 2026 results | August 2, 2026 |
| 2026 margin guidance | Non-GAAP gross margin about 64%, non-GAAP operating margin about 23.5% to 24%, adjusted EBITDA margin about 31.5% to 32% | Dexcom Q2 2026 results | August 2, 2026 |
| Full-year 2025 revenue | $4.662 billion reported revenue, up 15.6% | StockAnalysis and Dexcom FY2025 results | August 2, 2026 |
| Full-year 2025 net income | $836.3 million GAAP net income, $2.09 diluted EPS | StockAnalysis and Dexcom FY2025 results | August 2, 2026 |
| Balance sheet June 30, 2026 | Total assets of $6.46 billion, $1.24 billion long-term senior convertible notes, $2.62 billion stockholders equity | SEC Form 10-Q for quarter ended June 30, 2026 | August 2, 2026 |
| Trailing cash flow | $1.75 billion operating cash flow, $1.41 billion free cash flow | StockAnalysis DXCM statistics | August 2, 2026 |
| Analyst consensus | Strong Buy from 28 analysts, average price target $92.80, range $79 to $115 | StockAnalysis DXCM forecast | August 2, 2026 |
| Technical moving averages | 50-day SMA near $73.13, 200-day SMA near $67.75 | StockAnalysis DXCM statistics | August 2, 2026 |
| CGM market position | Mordor Intelligence estimated 2025 CGM revenue share at Abbott 52.83%, Dexcom 33.89%, and Medtronic 10.10% | Mordor Intelligence CGM market report | August 2, 2026 |
This DXCM AI stock analysis is an informational research tool. It is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if Dexcom results, product accuracy, reimbursement, competition, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
